Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Allergan, Johns Hopkins, Mirna, and More

Premium

Title: Methods, Compositions, and Drug-delivery Systems for Intraocular Delivery of siRNA Molecules

Patent Number: 8,586,556

Filed: Dec. 21, 2009

Lead Inventor: Robert Lyons, Allergan

The patent, its abstract states, claims "biocompatible intraocular drug-delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug-delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma, and proliferative vitreoretinopathy, among others."


Title: Therapy of p53 Mutant Colon Adenocarcinoma, Breast Cancer, and Lung Cancer

Patent Number: 8,586,557

Filed: March 25, 2010

Lead Inventor: Ygal Haupt, Peter MacCallum Cancer Institute

The invention, the patent's abstract states, provides "a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject … [by] administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia protein."

That agent, the patent notes, can be an siRNA or an shRNA.


Title: microRNAome

Patent Number: 8,586,725

Filed: Feb. 16, 2007

Lead Inventor: Jordan Cummins, Johns Hopkins University

"We have developed an experimental approach called miRNA serial analysis of gene expression — miRAGE — and used it to perform the largest experimental analysis of human miRNAs to date," the patent's abstract states. "Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers."


Title: Tissue-specific microRNAs and Compositions and Uses Thereof

Patent Number: 8,586,726

Filed: Jan. 15, 2010

Lead Inventor: Andrea Califano, Columbia University

"The invention provides for isolated nucleic acid sequences of newly discovered microRNAs that have been identified to exist in normal human B cells and/or in tumor-related human B cells using an integrated bioinformatics method and pipeline," the patent's abstract states.


Title: Synthetic Mimics of miR-34

Patent Number: 8,586,727

Filed: Feb. 3, 2012

Lead Inventor: Kevin Kelnar, Mirna Therapeutics

The invention, the patent's abstract states, comprises "miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.